Europe
Not only are women generally underrepresented in the biopharma industry, but compared to many of the top male executives, underpaid. Here’s a closer look at the top five female executives by pay in the biopharma industry.
Evotec is now a more powerful player in the infectious disease sector following the signing of its three-month-old deal to integrate Sanofi’s anti-infectives unit, including the majority of Sanofi’s infectious disease research portfolio and initiatives into its organization.
Ernest Loumaye, chief executive officer of Switzerland-based ObsEva, is excited about the potential opportunity to provide women a significant treatment for endometriosis-associated pain.
Biotech companies continue to make moves to strengthen senior leadership teams and drive growth. Here is a roundup of some noted movers and shakers for the week of June 11 - 15.
Teva has a new headache. As the company pushes forward with its cost-cutting strategies, the company reported it is scrapping its chronic cluster headache program with fremanezumab.
Shares of Motif Bio plc shot up late Thursday after the company announced it had completed its rolling submission of a New Drug Application to the U.S. Food and Drug Administration for its acute bacterial skin and skin structure infections (ABSSSI) treatment, iclaprim.
From CRISPR to spider silk there are some great scientific research stories out this week.
Novartis has walked into the European Congress of Rheumatology to make a case for two of its drugs, Cosentyx and canakinumab.
ViiV Healthcare, established in November 2009 by GlaxoSmithKline, Pfizer and Shiongi, reported positive results from its Phase III GEMINI-1 and -2 clinical trials.
Days after the U.S. Food and Drug Administration provided an expedited path forward for Sage Therapeutics’ depression treatment SAGE-217, the company snagged a deal worth $575 million.
PRESS RELEASES